Related Experiment Videos
Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method
D M Keeling1, R Luddington, J P Allain
1Department of Haematology, Addenbrooke's Hospital, Cambridge.
British Journal of Haematology
|January 1, 1997
Summary
Solvent detergent (SD) treatment of plasma reduces viral risk but significantly impacts von Willebrand factor (VWF) in cryoprecipitate. SD cryoprecipitate is unsuitable for von Willebrand disease but may serve hypofibrinogenaemia treatment.
Area of Science:
- Transfusion Medicine
- Hematology
- Viral Safety
Background:
- Single-donor blood components carry a risk of viral transmission.
- Viral inactivation procedures are crucial for blood product safety.
- Solvent detergent (SD) treatment is available for pooled fresh frozen plasma (FFP).
Purpose of the Study:
- To assess the suitability of cryoprecipitate derived from SD-treated plasma.
- To evaluate its efficacy in treating hypofibrinogenaemia and von Willebrand disease (VWD).
Main Methods:
- Cryoprecipitate was prepared from both control and SD-treated plasma.
- Assays were conducted for factor VIII, von Willebrand factor (VWF) activity and antigen, and fibrinogen content.
- Analysis included assessment of VWF high molecular weight multimers.
Main Results:
- SD cryoprecipitate showed significantly reduced VWF activity (36%) and antigen (37%) compared to controls.
- Fibrinogen levels in SD cryoprecipitate were preserved at 72% of control values.
- High molecular weight VWF multimers were absent in both SD plasma and SD cryoprecipitate.
Conclusions:
- Cryoprecipitate from SD-treated plasma is unsuitable for treating von Willebrand disease due to VWF multimer deficiency.
- It presents a potential alternative to untreated cryoprecipitate for managing hypofibrinogenaemic states, offering enhanced viral safety.